LIST OF TABLES

Table 1.1 Commonly used ion exchange resins for taste masking of MDTs 23
Table 1.2 Few commercially available mouth disintegrating tablet 24
Table 1.3 Commonly used natural flavoring agents for taste masking 26
Table 1.4 Commercially available mouth dissolving tablets 27
Table 1.5 Commonly used techniques in MDTs and comparative evaluation 29
Table 3.1 Pharmacokinetic parameters of levocetirizine diHCl 45
Table 4.1 Observation for taste evaluation of Levocetirizine diHCl Resin Complex 66
Table 4.2 Entrapped efficiency of levocetirizine in complexes 66
Table 4.3 Cumulative percentage drug release from complexes in simulated saliva 67
Table 4.4 Cumulative percentage drug release from complexes in 0.1N HCl 67
Table 4.5 Observation for taste evaluation of Levocetirizine diHCl BCD Complex 68
Table 4.6 Observation for taste evaluation of Levocetirizine diHCl by Mannitol 69
Table 4.7 Phase solubility studies of Cefixime and its complexes at gastric pH 70
Table 4.8 Phase solubility studies of Cefixime and its complexes at pH 6.2 71
Table 5.1 Composition of Formulation Trials using Superdisintegrant 74
Table 5.2 Composition of Formulation Trials using Pregelatinized starch 75
Table 5.3 Composition of Formulation Trials using Sublimation 76
Table 5.4 Composition of Formulation Trials using Effervescent 77
Table 5.5 Composition for Excipients screening Trials from Water soluble Excipients 78
Table 5.6 Composition for Excipients screening Trials from Effervescent Excipients 79
Table 5.7 Composition for Excipients screening Trials from Effervescent Excipients 80
Table 5.8 Composition of Formulation of MDTs of Levocetirizine by Sublimation 82
Table 5.9 Composition of Formulation of MDTs of Levocetirizine by Effervescent 83
Table 5.10 Observation of MDTs by Direct Compressed Effervescent tablet 83
Table 5.11a Observation of MDTs of Effervescent tablet by Wet Granulation Method 84
Table 5.11b Observation of MDTs of Effervescent tablet by Modified Wet Granulation Method 84
Table 5.12 Composition of Formulation of MDTs of Cefixime 85
Table 5.13 Parameter for in vitro Drug Release Study 87
Table 5.14a Evaluation Parameters of the MDTs of Levocetirizine prepared by sublimation 88
Table 5.14b Evaluation Parameters of the MDTs of Levocetirizine prepared by Effervescent 88
Table 5.15 Evaluation Parameters of the MDTs of Cefixime prepared by Effervescent 89
Table 5.16 in vivo Mouth disintegration time of the MDTs of Levocetirizine 89
Table 5.17 Cumulative percentage drug dissolved vs. time profile of the sublimed MDTs of Levocetirizine in simulated saliva 92
Table 5.18 Cumulative percentage drug release vs. time profile of the sublimed MDTs of Levocetirizine in 0.1N HCl 93
Table 5.19 Cumulative percentage drug release vs. time profile of the effervescent MDTs of Levocetirizine in simulated saliva 94
Table 5.20 Cumulative percentage drug release vs. time profile of the effervescent MDTs of Levocetirizine in 0.1N HCl 95
Table 5.21 Cumulative percentage drug release vs. time profile of the effervescent MDTs of Cefixime in simulated saliva 96
Table 6.1 Parameters for Permeability studies by non everted gut sac method 100
Table 6.2 Cumulative % drug Permeated from formulation C4 in comparison to pure drug 100
Table 6.3 Zone of Inhibition (mm) by Cefixime with concentration (mcg/ml) 103
Table 6.4 Observed zone of Inhibition (mm) with time (hrs) from animal study 106
Table 6.5 Plasma concentration (Cp) with time (hrs) of Cefixime and Formulation (C4) 107
Table 6.6 Pharmacokinetic parameters in animal after oral administration of Cefixime and Formulation (C4) 108
Table 6.7 Peak area versus concentration of Cefixime in HPLC analysis 110
Table 6.8 Level of plasma concentration (Cp) of Cefixime (mcg/ml) from rabbit after oral administration of pure drug and formulation (C4) 111
Table 6.9 Pharmacokinetic parameter of Formulation C4 in comparison to pure drug after oral administration in rabbits 112